We’re pleased to announce that Day One Biopharmaceuticals will serve as a presenting sponsor for the 2024 Pediatric Early Development Symposium (PEDS). This two-day virtual event, scheduled for October 9th and 10th, will bring together experts and stakeholders in pediatric cancer drug development to tackle the challenges and opportunities in the field. Representatives from Day One will participate in two sessions:
Session 1: “Charting the Regulatory Landscape in Pediatric Cancer Drug Development” with featured speaker Kimberly Lindstrom, PhD, Senior Vice President, Regulatory Science and GCP Quality at Day One
Session 2: “‘If You Build It, Will They Come?’ Exploring the Case for Investing in Pediatric Cancer Drug Development“, chaired by Sam Blackman, MD, PhD, Co-founder and Head of Research and Development at Day One
Founded in 2018, Day One Biopharmaceuticals is dedicated to addressing the urgent needs of children battling cancer. With a deep understanding of both the biological complexities of cancer and the pediatric community, Day One approaches drug development with a clear mission. Day One’s values tie closely to ours, as we accelerate the development of new childhood cancer treatments and address areas of unmet need in childhood cancer. Co-Founder and Head of Research and Development, Dr. Blackman, serves on our CureSearch Board of Directors and has been instrumental to our impact, including playing a leading role in organizing our annual Pediatric Early Development Symposium.
To learn more about Day One Biopharmaceuticals, visit: Day One.
Thank you to Day One for their invaluable support of PEDS as we collaborate to discover safer treatments for children facing cancer. [JN3] To register for 2024 PEDS, visit: curesearch.org/peds2024.
